The firm maintains a vulnerable capital structure with $12.0M in total liabilities against only $4.9M in equity, suggesting limited capacity to absorb further underwriting losses.
| Total Assets | 20.12M | 16.85M | 16.31M | 15.38M | 16.85M |
| Asset Growth % | 0% | 3.35% | 6.03% | -8.71% | - |
| Total Investment Assets | 149 | 49 | 0 | 0 | 0 |
| Long-Term Investments | 149 | 49 | 0 | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 14.14M | 13.12M | 16.17M | 14.77M | 15.67M |
| Cash & Equivalents | 1.34M | 2.98M | 1.95M | 1.22M | 1.56M |
| Receivables | 14.75M | 2.49M | 12.44M | 13.33M | 13.88M |
| Other Current Assets | 0 | 31.8K | 1.59M | 0 | 0 |
| Goodwill & Intangibles | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| PP&E (Net) | 5.9M | 3.45M | 57.97K | 578.78K | 1.18M |
| Other Assets | 32.14K | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.6M | 11.99M | 8.75M | 9.89M | 13.14M |
| Total Debt | 9.87M | 3.42M | 4.29M | 7.21M | 10.15M |
| Net Debt | 8.53M | 440.39K | 2.34M | 6M | 8.59M |
| Long-Term Debt | 2.01M | 0 | 1.58M | 3.4M | 5.31M |
| Short-Term Debt | 3.83M | 61.37K | 2.68M | 3.22M | 3.63M |
| Total Current Liabilities | 7.52M | 10.69M | 7.16M | 6.47M | 7.19M |
| Accounts Payable | 1.47M | 2.1M | 829.32K | 1.46M | 1.08M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.22M | 15K | 458.31K | 490.73K | 405.5K |
| Deferred Taxes | 38.75K | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 6.52M | 4.86M | 7.56M | 5.49M | 3.71M |
| Equity Growth % | 0% | -35.67% | 37.76% | 48.12% | - |
| Shareholders Equity | 6.28M | 4.86M | 7.56M | 5.49M | 3.71M |
| Minority Interest | 245.21K | 3.5K | 0 | 0 | 0 |
| Retained Earnings | -28.13M | -4.4M | 7.56M | 5.49M | 3.71M |
| Common Stock | 34.2M | 34.21M | 24.46M | 8 | 8 |
| Accumulated OCI | 211.5K | -24.95M | -24.46M | 0 | 0 |
| Return on Equity (ROE) | -169.84% | -194.55% | 31.77% | 38.79% | 53.38% |
| Return on Assets (ROA) | -52.31% | -72.9% | 13.08% | 11.07% | 11.74% |
| Equity / Assets | 32.42% | 28.86% | 46.37% | 35.69% | 21.99% |
| Debt / Equity | 1.51x | 0.70x | 0.57x | 1.31x | 2.74x |
| Book Value per Share | 4.17 | 3.11 | 5.58 | 4.05 | 2.74 |
| Tangible BV per Share | 4.17 | 3.11 | 5.58 | 4.05 | 2.74 |
Capital Adequacy and Liquidity
As reported in the 2024Q4 financial statements, BMGL maintains a total equity position of $4.9M against $12.0M in total liabilities, suggesting that the company's rapid expansion phase is currently consuming capital faster than it can be generated through its core medical service operations.
The current equity-to-liability ratio indicates a precarious capital structure that leaves little room for operational volatility. Investors should monitor whether the company's growth trajectory can reach a scale that stabilizes this capital base before further dilution or debt financing becomes necessary.
Based on the 2024Q4 figures, the company holds $5.4M in loss reserves, which, when viewed alongside a 126.7% combined ratio, suggests that current reserving practices may be insufficient to cover the underlying claims volatility inherent in their medical service delivery model.
The high combined ratio implies that for every dollar of premium earned, the company is paying out significantly more in claims and expenses. This suggests that the reserve levels may be subject to future adverse development if the current underwriting performance does not improve.
According to the latest quarterly data, the company's investment portfolio is negligible at $49, indicating that BMGL lacks a meaningful liquid asset buffer to support its $5.4M in loss reserves, which warrants further investigation into the firm's ability to meet unexpected claims obligations.
The absence of a substantial investment portfolio suggests that the company is operating with minimal float, forcing it to rely on incoming premiums to fund immediate claims payments. This structure appears highly sensitive to any disruption in patient volume or premium collection cycles.
As indicated by the 2024Q4 balance sheet, the company's reliance on equity to fund operations while maintaining a negative net margin of -106.78% suggests that the current balance sheet is highly vulnerable to external shocks or a tightening of capital market conditions.
The lack of meaningful investment assets combined with a high liability load suggests that the company's financial health is entirely dependent on its ability to achieve rapid operating leverage. If the current burn rate persists, the company may face significant challenges in maintaining its solvency ratios.
Quick answers to the most common questions about buying BMGL stock.
As of 2024, Basel Medical Group Ltd Ordinary Shares (BMGL) had total assets of $16.9M including $13.1M in current assets.
Basel Medical Group Ltd Ordinary Shares (BMGL) carries total debt of $3.4M, offset by $3.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Basel Medical Group Ltd Ordinary Shares (BMGL) has total shareholders' equity (book value) of $4.9M ($3.11 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Basel Medical Group Ltd Ordinary Shares (BMGL) reported a current ratio of 1.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.